Overview

Eribulin in Brain Metastases From HER2-negative Breast Cancer

Status:
Withdrawn
Trial end date:
2020-04-14
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of eribulin for treatment of HER2-negative breast cancer brain metastases (BCBM)
Phase:
Phase 2
Details
Lead Sponsor:
Institut Paoli-Calmettes
Collaborator:
Eisai Inc.